Results 141 to 150 of about 9,061 (176)

Low dose abemaciclib in heavily treated hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. [PDF]

Am J Cancer Res
Lu YR, Liu CT, Wu SC, Wu CC, Huang SY, Tsai CH, Chen YH.   +6 more
europepmc   +1 more source

Cardiovascular toxicity of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in HR+/HER2- breast cancer: a real-world study based on the FAERS database. [PDF]

Front Pharmacol
Ma S, Li L, Chen Y, Zhao Y.
europepmc   +1 more source

The microRNA Expression Signature of Lung Adenocarcinoma Harboring <i>EGFR</i> Mutations: Identification of Therapeutic Targets for EGFR-TKI Combination Therapy. [PDF]

Int J Mol Sci
Tokunaga T, Tomioka Y, Takeda AH, Ishihara Y, Nagata A, Kato M, Suetsugu T, Mizuno K, Aoki M, Ueda K, Seki N.   +10 more
europepmc   +1 more source

Perceptions and lived experiences with abemaciclib and endocrine therapy for early breast cancer: a rapid communication. [PDF]

Future Oncol
Harder H, Jenkins V, Fallowfield L.
europepmc   +1 more source

CDK4/6 inhibitors as conditional immune-priming agents in breast cancer: therapeutic windows, sequencing strategies, and rational combinations with immunotherapy, radiotherapy, and antibody-drug conjugates. [PDF]

Front Immunol
Zheng C, Pan Y, Zheng D, Pan Y.
europepmc   +1 more source

The Inhibitory Effect of Anastrozole on the Metabolism of Abemaciclib <i>In Vitro</i> and <i>In Vivo</i>. [PDF]

ACS Omega
Jin LH, Zhang ZY, Xu XY, Chen ZX, Chen J, Lan YB, Pan LL, Zhang XD.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Abemaciclib

Reactions Weekly
  +22 more sources